Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wow... can it get any better? When it's all said and done, A2-73 will be identified as the advent to a whole new platform of drugs.
I like that... guessing test scores instead of stock prices! <grin>
I think you're right, George. Why else bring in a new PR/IR company at this time?
Regarding double-blind tests with placebo...
Is it really necessary to incorporate a placebo in the testing? After all, it's been used in past trials (e.g. donepezil) so they should already know what to expect. Seems to me that the transitory property should apply here... If A>B and B>C, then A>C. In other words, if donepezil is better than placebo, then the double-blind test should be, both, vs. and with donepezil and not placebo. Also, not fair to the patients to get only a placebo.
Price action holding up well for a Tuesday. :)
Those of little faith and patience should definitely sell their shares here to the faithful longs who will buy and hold for the highly probable huge profits.
Re: "Dead money"
Well, maybe just for the time being. I'd surely hate to be out of it when the next announcement happens.
Then I stand corrected. I thought the closing price on 12/31 was around $4.50. My bad.
If that were the case, then I would think the avg $ amount for some would be sub $5.
If I were a fund mgr and had access to mega funds to buy into a promising biotech, I'd be piling in at sub $4, lowering my avg cost as much as possible. If I didn't it would likely be that either the risk/reward was too high to make that investment or I had restrictions on my purchase price.
From WhaleWisdom, as of Q4...
VANGUARD GROUP INC 460,820 $ 2,567,000 3292 new
MORGAN STANLEY 132,596 $ 738,000 4251 new
GEODE CAPITAL MANAGEMENT, LLC 121,977 $ 679,000 3091 new
BANK OF NEW YORK MELLON CORP 44,199 $ 246,000 3793 new
VERITABLE, L.P. 25,000 $ 139,000 714 new
GROUP ONE TRADING, L.P.(CALL) 24,600 $ 137,000 2785 new
CITADEL ADVISORS LLC(CALL) 22,700 $ 126,000 6583 new
GROUP ONE TRADING, L.P.(PUT) 20,900 $ 116,000 2890 new
CREATIVE PLANNING 12,720 $ 71,000 1839 new
WELLS FARGO & COMPANY 12,104 $ 68,000 5114 new
SIMPLEX TRADING, LLC(PUT) 190 $ 33,000 2275 new
CITADEL ADVISORS LLC(PUT) 5,600 $ 31,000 7807 new
GROUP ONE TRADING, L.P. 4,348 $ 24,000 3822 new
BLACKROCK FUND ADVISORS 3,874 $ 22,000 3933 new
BLACKROCK ADVISORS LLC 3,648 $ 20,000 3488 new
SIMPLEX TRADING, LLC(CALL) 113 $ 13,000 3119 new
BANK OF MONTREAL 2,000 $ 11,000 3589 new
TOWER RESEARCH CAPITAL LLC (TRC) 891 $ 5,000 2931 new
ALPHAMARK ADVISORS, LLC 700 $ 4,000 267 new
NEXT FINANCIAL GROUP, INC 250 $ 1,000 1668 new
TORTOISE INVESTMENT MANAGEMENT, LLC 250 $ 1,000 405 new
CITADEL ADVISORS LLC 100 $ 1,000 8828 new
On an avg price basis it makes perfect sense.
Just do the math.
If $5 isn't a barrier, then why do all of the institutions have an avg price above $5?
Bottom line from your articles: it all depends.
If they have a $5 restriction, then they haven't been purchasing recently.
Other than Vanguard, I initially felt the institutional ownership was on the light side...but then realized that they all mostly bought at prices between $5 and $6. The lack of recent purchases is likely due to the sub $5 stock price. 12-wk results or partnership news will change this in a big way.
After that presentation, I'm selling! As soon as it hits $20. :)
Hey Doc! For your presentation rating, check the stock price.
A rather disappointing presentation. I would think that many biotech investors would already know the history of 2-73 and results to date. Hope he states something more newsworthy(i.e. partnership prospects, etc.)
Ye of little faith!
Coiling the spring... stand back! ;)
Please stop with the "sky is falling" drama.
I'm still not ruling out the possibility of a PR on the 12-wk results by tomorrow, using today's PR as a sort of "curve ball" to the shorts. We'll see...
If 12-wk results meet or exceed expectations, I see this eventually running to between $10-$12 before any downward manipulation, with support being $8, if it even gets there. When partnership news is announced, then look out! All IMO.
It will be interesting to see what happens to the sp after it runs up on great 12-wk results (say, > $8?). Certainly there will be profit taking here, but It's doubtful there will be the extreme manipulation back down this time. Mainly because many will be expecting it. I invision only a 20-30% pullback just to spook weak hands out of their shares, then it surges higher on the next leg (> $10?). After all said and done, it would seem that $8 will be the next level of extreme support, until there's a partnership announcement...then Katie bar the door! Hey, just trying to anticipate what's to come next. GLTAL!
Excellent point!
Yes... but if it were not for the advice of his attorney you know the mouthy and arrogant punk would be responding to those questions, trying to outsmart them.
I'm thinking that Dr. M is playing this closer to the vest this time around, learning from the CTAD experience. I fully expect the 12-wk results to be released prior to the conference, then an "overview" of those results during the presentation. That's what my gut tells me. Shorts be damned!
Yeah, if they were already long. However, there's still a significant short position that needs to cover. They want to do it as cheaply as possible. They had better not wait too long.
They have to walk it down so they can buy/cover lower...
Every day that there's no premarket PR, then the shorts will play their nefarious games.
Are you new here?
12-wk data is due to come out, but since there is no "scientific" conference soon, it's believed that it will PR ahead of the biotech investors' conference next Tue. At least we're hoping!
They couldn't scare enough investors into selling low, so they run it up by covering, hoping to get them to sell at the high...then walk it back down for more short covering.
Yeah, the news that we're all awaiting should put a (temporary) stop to all this nonsense...which will then be at a much higher SP.
How do you know that the bulls and bears aren't the same traders, just switching sides to manipulate it?
Just the opposite... PR before the conference to generate big excitement heading into the conference. That's what I would do if I were Dr. M.
Since it's an investors conference and not scientific, I believe the 12-wk results will be PR'd either Friday, Monday or Tuesday pre-market...which will create huge attention for his presentation.
Don't be surprised if Dr. M issues a PR on Friday, Monday or Tuesday morning, ahead of the investors conference.
I was thinking more like bongo drums.
Welcome to PR week! Let's see who's still holding onto their shorts when the news is released. Kind of like musical chairs. The last to cover goes running to his mother!